Please log in to view this page
Username
Password
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...
IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...
